Lilly highlights brenipatide trials targeting depression relapse and alcohol use

Eli Lilly’s September 17 program at Psych Congress 2026 highlighted brenipatide studies targeting major depressive disorder and alcohol-use disorder, bringing renewed attention to whether GIP/GLP-1 receptor activation can support psychiatric treatment. The development matters because these trials ask about depression relapse and drinking patterns—outcomes that require evidence beyond a drug’s effects on weight or metabolism.

Lilly’s conference page lists separate posters covering its RENEW-MDD-1 depression trial, two RENEW alcohol trials, and clinical data supporting dose selection. The verified materials establish the scope of the research program; they do not establish that brenipatide prevents depression relapse or reduces harmful drinking.

The chronology is important. These are existing studies featured in a September conference program. Lilly’s trial pages date the depression study to February 2026 and the alcohol studies to October 2025. The conference listing should not be interpreted as the launch of three new trials.

Depression: testing whether benefit lasts

RENEW-MDD-1 is a phase 3 study with a planned enrollment of 1,000 adults aged 18–75. It compares investigational brenipatide plus standard care with placebo plus standard care, assessing whether the drug delays the return of major depressive symptoms.

Lilly’s trial summary requires participants to be receiving stable standard care. Its investor materials identify the primary endpoint as time from randomization until a participant meets a criterion for depression relapse. That makes the clinical question distinct from whether a medicine rapidly improves an acute depressive episode.

The sponsor lists a study timeline extending to February 2028. That is a planned research milestone, not a promised date for publication or regulatory action. Enrollment targets likewise describe the intended study size, rather than the number of people who have completed treatment.

Alcohol studies measure drinking outcomes

RENEW-ALC-1 and RENEW-ALC-2 are phase 3 studies, each with a planned enrollment of 1,100 adults aged 18–75. The first concerns moderate-to-severe alcohol-use disorder; the second concerns alcohol-use disorder with hazardous alcohol use. Both compare brenipatide with placebo.

Lilly’s published trial overview identifies changes in drinking patterns, assessed using the Timeline Followback method, as the primary outcome for the alcohol studies. Participant involvement is expected to last approximately 56 weeks, and the sponsor’s trial pages extend the study timelines into April 2028.

UCLA Health independently lists RENEW-ALC-2 as an interventional phase 3 study and describes its purpose as testing efficacy and safety. Its eligibility criteria require participants to be seeking treatment and motivated to stop or reduce drinking. Those requirements matter when interpreting eventual results: findings in a selected trial population may not transfer directly to everyone with alcohol-use disorder.

What remains unanswered

The alcohol trial’s exclusions also limit its reach. UCLA lists advanced liver disease and certain recent suicide-related findings among the reasons a person cannot participate. Consequently, even a favorable result would require care before extrapolating to people with these conditions.

For all three studies, the clinically important questions include the size and durability of any benefit, adverse events, treatment discontinuations, and how consistently results hold across patient groups. A phase 3 designation describes a stage of development; it does not answer those questions.

For healthspan research, the relevant possibility is better long-term control of illnesses that can disrupt daily function and sustained health. These studies are not tests of lifespan extension or biological-age reduction. Their practical contribution will depend on whether brenipatide produces meaningful psychiatric benefits with acceptable safety in the populations actually studied.